

# FDA-Approved Therapeutics and Diagnostics

## From Which Dana-Farber Receives Royalty Income

### DRUGS:

Commercial Name	Product Type	Type	Company	Year Approved
<b>Uplizna (Inebilizumab-cdon)</b>	Anti-CD19 Ab	Biologic	Horizon Therapeutics	2020
<b>Rydapt (Midostaurin)</b>	FLT3 inhibitor	Drug	Novartis	2017
<b>Imfinzi (Durvalumab)</b>	Anti-PD-L1 Ab	Biologic	AstraZeneca	2017
<b>Bavencio (Avelumab)</b>	Anti-PD-L1 Ab	Biologic	EMD SERONO INC	2017
<b>Tecentriq (Atezolizumab)</b>	Anti-PD-L1 Ab	Biologic	Genentech / Roche / Chugai	2016
<b>Keytruda (Pembrolizumab)</b>	Anti-PD-1 Ab	Biologic	Merck	2014
<b>Opdivo (Nivolumab)</b>	Anti-PD-1 Ab	Biologic	Bristol-Myers Squibb	2014

### DIAGNOSTICS:

Commercial Name	Product Type	DSCI Involvement	Company	Year Approved
<b>Ventana MMR RxDx Panel</b>	Mismatch Repair Deficiency Diagnostic	Methods of Use	Ventana / Roche	2021
<b>myChoice HRD CDx</b>	Cancer-related germline mutation detection system	Methods of Use	Myriad Genetic Laboratories	2019
<b>Ventana pd-I1(sp142) CDX Assay20</b>	Anti-PD-L1 Ab Diagnostic	Composition of Matter	Ventana / Roche	2016
<b>PD-L1 IHC 22C3 PharmDx</b>	Anti-PD-L1 Ab Diagnostic	Composition of Matter	Dako	2015
<b>PD-L1 IHC 28-8 PharmDx</b>	Anti-PD-L1 Ab Diagnostic	Composition of Matter	Dako	2015
<b>Therascreen EGFT RGQ PCR Kit</b>	EGFR Mutation Diagnostic	Methods of Use	QIAGEN	2013
<b>Cobas EGFR mutation test</b>	EGFR Mutation Diagnostic	Methods of Use	Roche	2013
<b>CA 15-3 Antibody RIA</b>	Anti-CA 15-3 Diagnostic	Composition of Matter	CENTOCOR / Fujirebio	1997
<b>CA 125 Antibody RIA</b>	Anti-CA 125 Diagnostic	Composition of Matter	CENTOCOR / Fujirebio	1987